Overview

A Chronic Obstructive Pulmonary Disease (COPD) Trial Investigating Roflumilast on Safety and Effectiveness in China, Hong Kong and Singapore:

Status:
Completed

Trial end date:
2012-05-01

Target enrollment:

Participant gender:

Summary

The aim of this trial is to determine the efficacy, safety and tolerability of 500 µg Roflumilast tablets once daily in patients with COPD in China, Hong Kong, and Singapore.

Phase:

Phase 3

Details

Lead Sponsor:

AstraZeneca
Takeda

Treatments:

Albuterol